Global Postoperative Nausea and Vomiting Market Size, Share, and COVID-19 Impact Analysis, By Treatment Type (Serotonin Antagonists, Dopamine Antagonists, Steroids, NK-1 Receptor Antagonists, Non-Pharmacological Treatment), By Distribution Channels (Hospitals, Retails Pharmacies, Online Distribution, Hyper, Super Markets), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030Industry: Healthcare
Global Postoperative Nausea and Vomiting Market Insights Forecasts to 2030
- The Global Postoperative Nausea and Vomiting Market Size was valued at USD 1805.6 Million in 2021.
- The Market is growing at a CAGR of 3.55% from 2022 to 2030.
- The Worldwide Postoperative Nausea and Vomiting Market Size is expected to reach USD 2471.3 Million by 2030.
- Europe is expected to grow the fastest during the forecast period.
Get more details on this report -
The Global Postoperative Nausea and Vomiting Market Size is expected to reach USD 2471.3 million by 2030, at a CAGR of 3.55% during the forecast period 2022 to 2030.
Postoperative nausea and vomiting (PONV) are amongst the most frequently occurring complications in patients undergoing surgery with general anesthesia. Postoperative nausea and vomiting are complex and significant problems in anesthesia practice, with the growing trend toward ambulatory and day-care surgeries. In medicine, surgery after anesthesia, nausea and vomiting are distressing symptoms. Uncomplicated PONV rarely goes beyond 24 hours post operatively and problematic PONV however is more multifactorial in origin and can be difficult to treat effectively. It may resolve without any complications in some cases, but it may require unexpected hospitalization and delay recovery room discharge. The possible complication includes in PONV, such as increased intracranial pressure, wound dehiscence, aspiration, esophageal rupture, dehydration, and pneumothorax.
This research report categorizes the global postoperative nausea and vomiting market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global postoperative nausea and vomiting market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the global postoperative nausea and vomiting market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.
Global Postoperative Nausea and Vomiting Market Report Coverage
|Market Size in 2021:||USD 1805.6 Million|
|Forecast Period 2021-2030 CAGR:||3.55%|
|2030 Value Projection:||USD 2471.3 Million|
|Historical Data for:||2017-2020|
|No. of Pages:||200|
|Tables, Charts & Figures:||130|
|Segments covered:||By Treatment Type, By Distribution Channels, By Region, and COVID-19 Impact Analysis|
|Companies Covered:||Novartis AG, GlaxoSmithKline plc, Merck and Co., Inc, Pfizer, Inc., Bayer AG, AstraZeneca, AbbVie, Sanofi, Boehringer Ingelheim Pharmaceuticals, Inc. Teva Pharmaceutical Industries Ltd, Ani Pharmaceuticals, Inc., Camurus AB, Eisai Corporation|
|Pitfalls & Challenges:||COVID-19 has the potential to impact the global market|
Get more details on this report -
The market is witnessing relatively moderate growth due to an increase in the patient population experiencing post-operative nausea and vomiting and a rise in the rate of adoption of combination therapies as well as non-pharmacological treatment modes globally during the forecast period. Rising R&D activities, growing demand for advanced therapies, and more focus of major pharmaceutical companies toward novel treatment therapies will provide beneficial opportunities for the global postoperative nausea and vomiting treatment market during the forecast period. Moreover, the rise in healthcare expenditure and growing government initiatives for spreading awareness programs are the factors that will expand the global postoperative nausea and vomiting treatment market.
Major factors restraining the growth of the postoperative nausea and vomiting market include the large number of surgeries performed and the rise in the rate of postoperative complications, such as dizziness, vomiting, and nausea. However, strict regulatory approvals and high healthcare expenditures are predicted to hamper the growth of the PONV market during the forecast period.
In 2021, the serotonin antagonists segment is dominating the market with the largest market share over the forecast period.
Based on treatment type, the global postoperative nausea and vomiting market is segmented into serotonin antagonists, dopamine antagonists, steroids, NK-1 receptor antagonists, and non-pharmacological treatment. In the treatment of postoperative nausea and vomiting, pharmacological anti-emetics for prophylaxis of postoperative nausea and vomiting in adults the drugs included in this segment are, serotonin antagonists; such as ramosetron, granisetron, palonosetron, ondansetron, dolasetron, and tropisetron. Another type of treatment, which is neurokinin-1 (NK-1) receptor antagonists; includes aprepitant and rolapitant drugs. In steroids, the drug includes, such as dexamethasone and methylprednisolone. Among these, the serotonin antagonists’ segment is dominating the market with the largest market share due to its safety profile and effectiveness as well as the physician gives first preference to the drug treatment in the management of postoperative nausea and vomiting.
The non-pharmaceutical treatment is expected to grow the market during the forecast period, due to cost-effectiveness. This treatment such as acupressure, acupuncture, and electrical acustimulation in the treatment of postoperative nausea and vomiting.
In 2021, the hospital segment is dominating the market over the forecast period.
Based on the distribution channel, the global postoperative nausea and vomiting market is segmented into hospitals, retails pharmacies, online distribution, hyper, and super markets. Among these, the hospital segment is dominating the market over the forecast period due to the rising investment in the hospital sector, particularly in emerging countries, which is boosting the number of hospitals.
Regional Segment Analysis of the postoperative nausea and vomiting market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is dominating the market with the largest market share during the forecast period
Get more details on this report -
North America accounted largest market share over the forecast period due to the presence of a large base of surgical patients as well as readiness among patients to pay extra money to avoid post-operative complications are expected to drive postoperative nausea and vomiting market. Furthermore, the presence of key players, a well-developed healthcare sector, and increasing awareness in this country is considered the growth of the market share during the forecast period.
Europe is also expected second leading region with the largest market share growth of postoperative nausea and vomiting market owing to rising surgical patient rates and a rise in R &D expenditure in pharmaceuticals.
The report offers the appropriate analysis of the key organizations/companies involved within the global postoperative nausea and vomiting market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Novartis AG
- GlaxoSmithKline plc
- Merck and Co., Inc
- Pfizer, Inc.
- Bayer AG
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd
- Ani Pharmaceuticals, Inc.
- Camurus AB
- Eisai Corporation
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In September 2019, the three therapies which are approved in the US for the management of postoperative nausea and vomiting after 2000 are Aloxi, Zuplenz, and Emend the PONV indication was removed from the Emend capsule as per the US prescription information; however, it remains in the labelling for generic aprepitant capsules. Other PONV drugs, which are discontinued in the US, are Kytril, Phenergan, and Compazine. The generic versions of most of the therapies approved before 2000 are currently utilized for the management of the Postoperative nausea and vomiting market.
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the Global Postoperative Nausea and Vomiting Market based on the below-mentioned segments:
Global Postoperative Nausea and Vomiting Market, By Treatment Type
- Serotonin Antagonists
- Dopamine Antagonists
- NK-1 Receptor Antagonists
- Non-Pharmacological Treatment
Global Postoperative Nausea and Vomiting Market, By Distribution Channel
- Retails Pharmacies
- Online Distribution
- Hyper and Super Markets
Global Postoperative Nausea and Vomiting Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?